Final Assessment: Tailoring Therapy to the nAMD Patient: Implementing Novel Treatment Strategies to Improve Outcomes

Credits:
0.5 AMA PRA Category 1 Credit(s)
Launch Date:
March 18, 2020
Expiration Date:
The accreditation for this activity has expired.

Primary Audience:

This certified CME activity is designed for retina specialists and eye care professionals involved in the medical management of patients with retina disorders.

Relevant Terms:

Anti-VEGF treatment, nAMD, Age-related Macular Degeneration, Neovascularization

Assess your improvements in knowledge and skills and see how your peers did!

Amy S. Babiuch, MD

Amy S. Babiuch, MD

Medical Retina Specialist  |  Cole Eye Institute

Assistant Professor Ophthalmology Case Western Reserve University

Associate Program Director Medical Retina Fellowship

WPSA Regional Focus Committee Chair

Amy S. Babiuch, MD is a medical retina specialist with specific interests in diabetic retinopathy, macular degeneration, and retinal vein occlusions. Dr. Babiuch's research includes imaging techniques and interpretations related to theses entities. She has been the PI or co-investigator of several studies related to these areas of research as well. Dr. Babiuch is also involved in several other roles outside of research including the Women’s Professional Staff Association of the Cleveland Clinic where she developed and now chairs the regional outreach committee. In addition, Dr. Babiuch was recently appointed to the role of associate director of the medical retina fellowship. Dr. Babiuch's dedication to advancement of women in STEM fields and teaching students, residents, and fellows suits her well for these roles.

Caroline Baumal, MD

Caroline Baumal, MD

Associate Professor 

Tufts University School of Medicine

New England Eye Center, Boston, MA

Caroline R. Baumal, MD is an Professor of Ophthalmology and Director of the Retinopathy of Prematurity Service at New England Eye Center, Tufts Medical Center in Boston, MA. She specializes in surgery and medical disorders of the retina and vitreous. Her long-term research interests include novel retinal imaging and drug development. Her clinical interests include age-related maculopathy, diabetic retinopathy, complex vitreoretinal surgery and pediatric retinal disorders.

 

Dr. Baumal completed medical school and ophthalmology residency at the University of Toronto after undergraduate studies at McGill University. She completed two fellowships: one at New England Eye Center, Boston in Medical Retina and Lasers and another in Vitreoretinal Diseases and Surgery at Wills Eye Hospital in Philadelphia. Dr. Baumal is Board Certified by the American Board of Ophthalmology. She has received multiple awards from various societies including the American Academy of Ophthalmology Senior Achievement award, The American Society of Retinal Surgeons Honor Award, The Retinal Hall of Fame, The Donald J. Gass Beacon of Sight Award from the Florida Ophthalmologic Society.  She is on the editorial board for Retina Cases and Brief Reports and Ophthalmic Surgery, Lasers and Imaging (OSLI) Retina. Dr. Baumal has authored over 100 publications, 28 book chapters on retinal diseases and recently edited the book Treatment of Diabetic Retinopathy.  She was previously Director of Education and the Residency program at New England Eye Center and is actively involved in teaching vitreoretinal fellows and residents.

 

David Eichenbaum, MD

David Eichenbaum, MD

Clinical Assistant Professor, Department of Ophthalmology
University of South Florida College of Medicine

President
Retina Vitreous Associates of Florida
Tampa, Florida

Dr. Eichenbaum is a board certified ophthalmologist, fellowship-trained in diseases and surgery of the vitreous and retina. He is a partner and Director of Research at Retina Vitreous Associates of Florida, a multi-MD sub-specialty vitreoretinal private practice and has been in practice since 2007. He completed the Medical Honors Program at the University of South Florida, earning his undergraduate and medical degree in Tampa. He completed his Ophthalmology residency at the University of South Florida, where he served as Chief Resident, and completed his two-year Surgical Retina fellowship at Tufts New England Eye Center and Ophthalmic Consultants of Boston.

Dr. Eichenbaum has served as Principal Investigator in over 40 Phase 1 though Phase 4 clinical trials, has published in numerous professional journals, published multiple textbook chapters, and has presented his work at the American Society of Retinal Specialists, American Academy of Ophthalmology, and the Association of Research and Vision in Ophthalmology meeting. He moderates at the Vit-Buckle Society and teaches nationally through both CME and commercial formats, lecturing on clinical science as well as common retinal diseases such as macular degeneration, diabetic eye disease, retinal vascular occlusions.  Dr. Eichenbaum serves on numerous Clinical and Scientific Advisory Boards, and serves on National Executive Steering Committees for both commercial and pipeline products.

Dr. Eichenbaum is a Fellow of the American Academy of Ophthalmology, sits on the Board of the Florida Society of Ophthalmology, serves as Vice President of Education for the Florida Society of Ophthalmology, and has served as Past President of the Tampa Bay Ophthalmic Society. In 2015, he received Michael R. Redmond, MD Outstanding Young Ophthalmologist Award from the Florida Society of Ophthalmology..

Dr. Eichenbaum is appointed as a Collaborative Associate Professor of Ophthalmology at the University of South Florida Morsani College of Medicine and co-chairs a monthly retina conference for the Ophthalmology department with his partners.

Nancy M. Holekamp, MD

Nancy M. Holekamp, MD
Director, Retinal Services
Pepose Vision Institute

Professor of Clinical Ophthalmology
Washington University School of Medicine

Nancy M. Holekamp, MD is a Professor of Clinical Ophthalmology and Visual Sciences at the Washington University School of Medicine in St. Louis, Missouri.  She is also Director of Retina Services at the Pepose Vision Institute in St. Louis.  Dr. Holekamp received her undergraduate Bachelor of Arts degree from Wellesley College Summa cum Laude.  She received her Medical Degree from the Johns Hopkins School of Medicine Alpha Omega Alpha.  Dr. Holekamp completed an internship in internal medicine and a residency in ophthalmology at the Washington University School of Medicine.  Her fellowship training in vitreoretinal surgery was with the Retina Consultants in St. Louis.

Dr. Holekamp has received numerous honors and awards, including being named in the “Best Doctors in America” annually since 2005 and is included in the US News & World Report Best Doctors list and Castle Connolly Top Doctors list.  She has received the Achievement Award, the Senior Achievement Award, and the Secretariat Award from the American Academy of Ophthalmology (AAO), and the Honor Award and Senior Honor Award from the American Society of Retina Specialists (ASRS).  She is co-founder and chair of Women in Retina.

Dr. Holekamp is actively involved in clinical research, having been principal investigator or sub-investigator in over 30 national clinical trials dealing with age-related macular degeneration, retinal vascular occlusion, and diabetic retinopathy.  Her efforts in research have resulted in 74 peer-reviewed publications, 21 book chapters, and more than 100 speaking invitations both nationally and internationally. 

She is a member of the major subspecialty societies, including the Retina Society and the Macula Society.  She acts as a reviewer for all the major ophthalmology journals and as a consultant to several ophthalmic pharmaceutical companies.   After 6 years on the American Academy of Ophthalmology Ethics Committee, she has developed an interested in medical ethics.

Roger A. Goldberg, MD, MBA

Roger A. Goldberg, MD MBA

Roger A. Goldberg, M.D., M.B.A., a native of Boston, graduated from both college and medical school at Yale University. He completed his residency in Miami at the Bascom Palmer Eye Institute, the nation’s top eye hospital and residency-training program. He returned to Boston for a fellowship in Vitreoretinal Diseases and Surgery at Tufts and Ophthalmic Consultants of Boston. Dr. Goldberg is board certified by the American Board of Ophthalmology, and is an active member of the American Society of Retinal Specialists, the Retina Society, and the American Academy of Ophthalmology.

Dr. Goldberg has published numerous research manuscripts and book chapters, including first-author publications in The New England Journal of Medicine, Ophthalmology, JAMA Ophthalmology, and American Journal of Ophthalmology. He serves as a Reviewer for Ophthalmology, AJO and Retina, and lectures at national and international meetings. He has been an investigator in over 30 clinical trials for age-related macular degeneration, retinal vein occlusion, and diabetic retinopathy, among others. His surgical interests include macular surgery, complex retinal detachment repair and complications of cataract surgery.

Between college and medical school, Dr. Goldberg spent a year as a Rotary Scholar at the University of Leiden, The Netherlands, and then worked as a healthcare consultant at McKinsey & Co. In addition to his medical training, Dr. Goldberg received an MBA from Yale and co-founded an ophthalmic startup.

Though loyal to his Boston sports teams, Dr. Goldberg is an enthusiastic transplant to the Bay Area, where he enjoys spending time outdoors with his wife and three children.

1.
Explain the differences in short-term and long-term outcomes with current neovascular AMD treatment options in clinical practice as compared to clinical trial outcomes.
2.
Describe the relationship between drugs, treatment frequency, visual, and anatomic outcomes.
3.
Develop best practices and recommendations to ensure optimal treatment outcomes for patients.
4.
Describe the existing barriers to treatment and ways to overcome them.
5.
Identify the newer compounds in development that may reduce treatment burden while maintaining efficacy.

Tailoring Therapy to the nAMD Patient: Implementing Novel Treatment Strategies to Improve Outcomes 
 
 
This continuing medical education activity is supported through educational grant from Genentech. 
 

Accreditation Statement

Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

Evolve Medical Education LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

The following fellows/faculty members have the following financial relationships with commercial interests:

Amy S. Babiuch, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Genentech; Grant/Research: Regeneron. 
Caroline Baumal, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Genentech, and Ocular Therapeutics; Speaker: Genentech, Novartis, and Carl Zeiss. 
David Eichenbaum, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alimera Sciences, Allergan, Allegro, Clearside Biomedical, Eyepoint Pharmaceuticals, Genentech, Orbit Biomedical, Notal Vision, Novartis, Opthotech, and Regeneron; Grant/Research Support: Alimera, Allergan, Chegdu, Clearside Biomedical, Genentech, Mylan, Novartis, Opthea, and Opthotech; Speaker: Allergan plc., Genentech, and Novartis; Stock/Shareholder: Boston Image Reading Center, Humera, and US Retina.
Roger A. Goldberg, MD, MBA, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Carl Zeiss, Genentech, and Regeneron; Grant/Research Support: Aerie Pharmaceuticals, Carl Zeiss, Genentech, Graybug, Novartis, and Santen; Speaker: Allergan, Genentech, and Novartis. 
Nancy M. Holekamp, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant:  Allergan, Genentech, Lineage, Gemini, Novartis, Regeneron, and Viewpoint Therapeutics. Grant/Research Support: Genentech, Gemini, Gyroscope, and Notal Vision; Speaker: Allergan, Genentech, Novartis, Regeneron, and Spark; Stock/Shareholder: Katalyst. 

 

Editorial Support

Erin K. Fletcher, MIT, director of compliance and education, Evolve, has no financial relationships with commercial interests.

Susan Gallagher-Pecha, director of client services and project management, Evolve, has no financial relationships with commercial interests.

Cassandra Richards, director of education development, Evolve, has no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.